More about Poly Medicure Limited
Fundamentals for Poly Medicure Limited
Regulatory Filings for Poly Medicure Limited
IndiGo Implements Steep Fuel Surcharge as Iran Conflict Sends Jet Fuel Costs Soaring
The RBI's New Forex Fortress: Defensive Maneuvers in an Era of Oil Shocks
India's Fiscal Milestone: GST Collections Breach ₹2 Lakh Crore Mark for the First Time
AI Disruption Accelerates: Oracle Layoffs Raise Alarms for India’s Tech Workforce
Fundamentals for Poly Medicure Limited
Business Operations:
Sector: HealthcareIndustry: Medical Instruments & Supplies
Poly Medicure Limited manufactures and sells medical devices in India and internationally. It offers infusion devices, such as I.V. cannulas, mid line catheters, arterial cannula, three way stop cocks, I.V. infusion sets, manifolds, safety winged infusion sets, T-type extension sets, stylet/mandrin with luer locks, vial access spikes, measured volume fluid administration sets, extension lines, central venous catheters, CVP manometers, needle free connectors, pre filled syringes, vascular accesses, and blood administration sets. The company also provides nasogastric and infant feeding tubes, gastro-duodenal feeding tubes, and umbilical catheters; urine collection bags, foley balloon catheters, irrigation sets, urine drainage catheters, and urine collection bags with measured volume meters; and endotracheal and tracheostomy tubes, mucus extractors, ventilator circuits, bain circuits, catheter mounts, spinal needles, HME filters, and laryngeal mask airways. It offers oncology products; endo bronchial suction catheters, oxygen catheters, respiratory exercisers, nasal oxygen cannulas, oro-pharyngeal airways, variable concentration masks, oxygen mask with reservoirs, fixed concentration masks, and aerosol therapy masks; and dialyzers, blood lines, dialysis systems, fistula needles, haemodialysis catheters, and peritoneal dialysis and transfusion sets. The company provides closed wound suction units, under water seal drainage systems, high pressure vacuum bottles, yankauer suction sets, and thoracic drainage catheters; blood collection tubes, safety blood collection sets, blood collection needles, ESR pipettes, and luer adaptors; blood bag systems; face protective shields, polymasks, and viral transport medium kits; and insulin syringes, sputum collectors, dry brushes, umbilical cord clamps, luer locks, cannula fixators, injection stoppers, luer lock injection sites, universal caps, and ECG electrodes. The company was incorporated in 1995 and is based in New Delhi, India.
Revenue projections:
Poly Medicure Limited is projected to see lower revenues than in the previous year, a trend that usually concerns investors. Declining revenues often harm a company's profitability, leading investors to exercise caution as they weigh the potential risks of continued financial downturns.
Financial Ratios:
| currentRatio | 3.88500 |
|---|---|
| forwardPE | 36.15006 |
| debtToEquity | 8.16900 |
| earningsGrowth | 0.00600 |
| revenueGrowth | 0.05700 |
| grossMargins | 0.67238 |
| operatingMargins | 0.20220 |
| trailingEps | 35.62000 |
| forwardEps | 43.98333 |
Poly Medicure Limited's current ratio of 3.885 highlights the company's solid liquidity, indicating that it can easily service its short-term debt. Poly Medicure Limited's ample cash reserves and current assets ensure that the company is well-positioned to meet its immediate financial liabilities.
POLYMED's positive gross and operating margins reflect its profitability and efficiency. These metrics demonstrate the company's ability to manage costs effectively while generating strong revenue, highlighting its solid financial health and operational effectiveness.
POLYMED's forward EPS being higher than its trailing EPS indicates that the company is expected to achieve greater profitability this financial year. This suggests improving earnings and a stronger financial position compared to the previous year's performance.
Price projections:
POLYMED's price projections have gradually decreased, reflecting a less optimistic view of the company's future performance. Analysts are adjusting their expectations, suggesting potential concerns about POLYMED's ability to meet previous growth targets.
Recommendation changes over time:
Analysts are favoring POLYMED with a buy bias, highlighting the stock's potential as a solid investment. This recommendation might drive more investors to consider POLYMED as a secure and profitable option for their money, contributing to a broader positive sentiment in the market.
DISCLAIMER: We provide information and our musings based on events, but nothing on this site can be considered professional advice of any kind.
If you have enjoyed reading, spread the word:
Good prospects:
Companies with the best and the worst fundamentals.
Latest Regulatory Filings for NSE500
Companies with the best and the worst technicals.
U.S. Labor Market in 2026: JOLTS and Consumer Confidence Reveal Why Hiring Cooled Without Unemployment Spike
Lending Unleashed: Assessing the Impact of the Federal Reserve’s Capital Rollback
Calendar Collision: How Mahavir Jayanti's Overlap With Fiscal Year-End Reshapes India's Tax-Loss Harvesting Landscape